Novartis (NYSE: NVS) reported Q3 EPS of $1.29, $0.04 better than the analyst estimate of $1.25. Revenue for the quarter came in at $12.41 billion versus the consensus estimate of $12.25 billion.

2017 Group outlook re-confirmed; net sales expected to be broadly in line with prior year (cc), core operating income expected to be broadly in line or decline low single digit (cc).

For earnings history and earnings-related data on Novartis (NVS) click here.